AIM ImmunoTech Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: NYSE
DilutionScan read 44 of AIM ImmunoTech Inc.'s SEC filings and found 16 warrant series, 3 convertibles, 2 ATM programs, 1 equity line, 2 shelf registrations, 6 S-1 registrations and 7 completed offerings on file for AIM. The latest dilution event on file is a securities exchange on Sep 8, 2026. Analysis updated Nov 1, 2026.
Signal8 Summary
AIM
Going-concern warning and severe dilution
Snapshot
AIM ImmunoTech is a micro-cap biotech in financial distress. The company generated only $88K in revenue in FY 2025, a 48% drop from the prior year, while losing $14.0M in net income. Its cash position is critically tight, with just $993K in cash against $4.9M in debt, resulting in a cash runway of only 3.1 months at current burn rates. To survive, the company has been aggressively raising capital through dilutive equity offerings and warrant exercises, including a recent $2.4 million financing and a $4.2 million warrant exercise.
What's Happening Right Now
- : AIM completed enrollment in its Phase 2 pancreatic cancer study ahead of schedule, with the final subject scheduled for treatment in mid-June 2026.
- : The company announced a $2.4 million financing via a registered direct offering and private placement to fund clinical trials and working capital.
- : Investors exercised outstanding warrants for approximately $4.2 million in gross proceeds, providing additional cash for general corporate purposes.
- : The company reported a 50% objective response rate in a Phase 2 ovarian cancer trial combining Ampligen with other therapies.
- : Auditors issued a going-concern emphasis of matter for FY 2025, signaling serious doubt about the company's ability to continue operating.
